Skip to main content
MyDeficiencies

Insulin lispro

Fast-Acting Insulin Analogue

Also sold as Humalog, Admelog, Lyumjev.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Insulin lispro has no classical drug-nutrient depletion mechanism in the pharmacokinetic sense. It is a 51-amino-acid peptide hormone analog given by subcutaneous or intravenous injection, not metabolized by CYP450 enzymes, not orally absorbed (so chelation, gastric-pH, transporter-competition, and bile-acid mechanisms of nutrient interference do not apply to the drug itself), and cleared by receptor-mediated proteolytic degradation, chiefly hepatic and renal, rather than by renal tubular excretion that could waste nutrients. What it does have is direct, well-documented hormone pharmacology: insulin lispro's own U.S. prescribing information states that, like all insulin products, it "shifts potassium from the extracellular to intracellular space," which can cause clinically significant hypokalemia. This is an on-label, drug-named finding, but it is a redistribution of existing body potassium, not a dietary deficiency, and it is graded and framed as a bounded disturbance rather than a supplementation target.

Insulins and analogues for injection, fast-acting · ATC A10AB04 · also sold as Humalog and Admelog and Lyumjev (lispro-aabc) and Insulin Lispro (generic/biosimilar) · reviewed 2026-09-20. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Insulin lispro in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: two or more independent Tier A sources, this drug in the studied cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: at least one Tier A source with this drug in the cohort showing a real deficit or disturbance, but bounded by exposure window, subgroup, frequency, or a functional (not just circulating) measure.
Yellow — Low
low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. A disclosed gap in the literature or in what could be accessed during this review, never reworded as reassurance.

What the research found

Potassium

Orange — Moderate

See study details

Insulin lispro drives a dose-related shift of potassium into cells and can cause clinically significant hypokalemia; the drug's own label names this risk directly, but it is concentrated in IV administration, DKA correction, and patients on other potassium-lowering drugs, not routine mealtime subcutaneous dosing.

Full detail and limits

What the grade means here: moderate: at least one Tier A source with this drug in the cohort showing a real deficit or disturbance, but bounded by exposure window, subgroup, frequency, or a functional (not just circulating) measure. Orange

Limits on what this shows

  • Key negative/null: No insulin lispro-specific human trial quantifying magnitude of potassium drop in routine subcutaneous mealtime dosing was located; the effect is understood, from the general insulin/electrolyte pharmacology literature, to be dose- and route-dependent (larger with IV/high-dose use than typical subcutaneous replacement dosing).
  • At-risk subgroups: Renal impairment (also flagged in the label for reduced insulin clearance), concurrent potassium-lowering drugs (diuretics, beta-agonists), IV administration, DKA correction, vomiting/diarrhea (StatPearls' general Insulin monograph separately warns against insulin use during vomiting/diarrhea because these already cause a hypokalemic state).

Regulatory status

On-label warning, named specifically for HUMALOG (insulin lispro), in the U.S. prescribing information, Warnings and Precautions section.

Population evidence

Regulatory label statement (Tier A, drug-named, mechanism-based warning, not a quantified trial); StatPearls' dedicated Insulin Lispro monograph repeats the same drug-specific language (Tier B). A small (n=12) veterinary trial of subcutaneous lispro insulin protocols in feline DKA reported low serum sodium, potassium, phosphate, and magnesium during treatment (2019; Tier B, animal, drug-named, but full journal/PMID could not be confirmed during this review due to repeated PubMed access blocks — see sources list).

Mechanism

Named: insulin binding to its receptor stimulates Na+/K+-ATPase activity, driving potassium into cells independent of any change in total body potassium; StatPearls' Refeeding Syndrome monograph describes the same pathway (glycolysis-linked phosphate uptake plus direct Na+/K+-ATPase stimulation) for the parallel phosphate shift.

Counter-evidence held on record

No source contradicts the existence of the shift; disagreement in the literature is about magnitude, understood to be small and self-limited at typical subcutaneous replacement doses and larger during IV correction of hyperglycemia/DKA. No human trial with quantified lispro-specific magnitude data was located to confirm the size of the effect at routine doses. This is a redistribution of existing body potassium, not a nutritional deficiency. Do not present this entry as grounds for routine potassium supplementation; serum potassium should be monitored and managed clinically, especially with renal impairment, IV/high-dose use, DKA correction, or concurrent potassium-lowering drugs.

Phosphate

Yellow — Low

See study details

The same glucose-uptake mechanism that shifts potassium intracellularly also drives phosphate into cells, a recognized cause of hypophosphatemia during insulin treatment of hyperglycemia/DKA and during refeeding; no primary human evidence specific to insulin lispro was found beyond a small veterinary trial.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: No insulin lispro-specific human trial reporting phosphate outcomes was located; PubMed searches combining "insulin lispro" with "phosphate" returned only the single veterinary trial and no human data.
  • At-risk subgroups: DKA correction (especially IV/high-dose insulin use), refeeding syndrome, malnourished patients starting insulin therapy.

Regulatory status

Not addressed in the HUMALOG label reviewed (label discusses potassium specifically, not phosphate).

Population evidence

StatPearls' Refeeding Syndrome monograph (Tier C, not lispro-specific) names the mechanism directly: rising glucose triggers insulin release, which drives phosphorus and potassium intracellularly via glycolysis-linked uptake and direct Na+/K+-ATPase stimulation. A 2019 veterinary trial of lispro insulin protocols in feline DKA (n=12; Tier B, drug-named) reported low phosphate concurrent with treatment, though full bibliographic detail could not be confirmed during this review.

Mechanism

Named: insulin-stimulated cellular glucose uptake is accompanied by phosphate co-transport into cells, lowering serum phosphate during rapid correction of hyperglycemia.

Counter-evidence held on record

No source contradicts the mechanism; the gap is the absence of insulin lispro-specific human quantification, not evidence against the effect. Mechanistically plausible and well characterized for insulin as a class in DKA/refeeding contexts, but not verified with primary human data for insulin lispro specifically. Do not present as an established lispro-specific finding, and make no phosphate dosing recommendation from this entry.

Magnesium

Yellow — Low

See study details

Low magnesium was reported alongside low sodium, potassium, and phosphate during lispro-based DKA treatment in a small veterinary trial, but the cellular mechanism for insulin-driven magnesium shift is explicitly less well characterized than for potassium or phosphate.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: No insulin lispro-specific human trial measuring magnesium was located. The disease-state study above found magnesium disturbance associated with diabetes generally, which does not distinguish a drug effect from the underlying condition.
  • At-risk subgroups: DKA correction, refeeding syndrome, malnourished patients starting insulin therapy.

Regulatory status

Not addressed in the HUMALOG label reviewed.

Population evidence

The same 2019 feline DKA trial (n=12; Tier B, drug-named lispro protocol) reported low serum magnesium concurrent with treatment. A separate human disease-state study, "Zinc, copper and magnesium status in insulin-dependent diabetes" (1994; PMID 7664536), reports magnesium disturbance in insulin-dependent diabetes but studies the disease state, not insulin therapy as the variable, and does not stratify to insulin lispro; treated as background context, not supporting evidence (Hard Rule 6, confounding by indication).

Mechanism

Partially named: StatPearls' Refeeding Syndrome monograph states explicitly that magnesium's "mechanism of involvement in refeeding syndrome is less understood" than the glycolysis/Na+/K+-ATPase pathway that explains potassium and phosphate shifts.

Counter-evidence held on record

The mechanism itself is weaker/less established in the literature reviewed than for potassium or phosphate; this is recorded as a limitation on the grade, not a contradiction of the finding. Weaker mechanistic basis than the potassium and phosphate entries above. Do not present as an established lispro-specific finding, and make no magnesium dosing recommendation from this entry.

  • Zinc, copper and magnesium status in insulin-dependent diabetes. 1994. PMID 7664536. — Human disease-state study; reduced serum zinc reported in insulin-dependent diabetes patients versus controls.Studies the diabetes disease state, not insulin therapy as the variable; confounded by indication (Hard Rule 6). Used only as background context for the Magnesium entry, not as supporting evidence for a drug effect.

Thiamine

Yellow — Low

See study details

Insulin release (endogenous or administered, including insulin lispro) is a recognized trigger of refeeding syndrome, in which increased carbohydrate metabolism raises thiamine demand and can precipitate acute thiamine deficiency; this is not specific to insulin lispro and applies to any insulin used to drive glucose uptake in a malnourished patient.

Full detail, limits and 3 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: No insulin lispro-specific study was located; the mechanism as described in the reviewed sources centers on carbohydrate/glucose load and refeeding physiology generally, with insulin as one part of a multifactorial process, not insulin dosing in a well-nourished patient on routine therapy.
  • At-risk subgroups: Malnourished or chronically underfed patients beginning any insulin therapy (including lispro) alongside carbohydrate or glucose administration; classic refeeding-syndrome risk groups (eating disorders, chronic alcohol use, prolonged fasting, bariatric patients).

Regulatory status

Not addressed in the HUMALOG label reviewed.

Population evidence

Narrative reviews of refeeding syndrome (Walmsley, 2013, PMID 24251716; De Silva & Nightingale, 2020, PMID 32884632; Maiorana et al., 2014, PMID 24985016) describe insulin release as central to the pathophysiology of refeeding-associated electrolyte and vitamin shifts, and link increased carbohydrate metabolism to thiamine depletion. None stratify by insulin formulation (Tier C, class-level).

Mechanism

Named at the class level: carbohydrate/glucose administration stimulates insulin release, driving cells into anabolic, carbohydrate-oxidizing metabolism that increases consumption of thiamine as a cofactor (pyruvate dehydrogenase, transketolase); the reviewed sources attribute this to increased metabolic demand during refeeding rather than to a direct insulin-thiamine interaction.

Counter-evidence held on record

None found contradicting the mechanism; the limitation is that all located sources are class-level, narrative reviews rather than insulin lispro-specific quantitative studies. Bounded strictly to malnourished/refeeding-risk patients, not general use of insulin lispro in routine diabetes management. Standard refeeding-syndrome clinical protocols already address thiamine prophylaxis in this population; this dossier makes no independent thiamine dosing recommendation.

  • Walmsley RS. Refeeding syndrome: screening, incidence, and treatment during parenteral nutrition. J Gastroenterol Hepatol. 2013. PMID 24251716. — Narrative review; insulin release central to refeeding-syndrome pathophysiology and anabolic electrolyte/vitamin shifts. Class-level.
  • De Silva A, Nightingale JMD. Refeeding syndrome: physiological background and practical management. Frontline Gastroenterol. 2020. PMID 32884632. — Narrative review; carbohydrate load raising plasma insulin and driving glucose/electrolyte shifts. Class-level.
  • Maiorana A, Vergine G, Coletti V, et al. Acute thiamine deficiency and refeeding syndrome: similar findings but different pathogenesis. 2014. PMID 24985016. — Case-based discussion of thiamine deficiency in relation to electrolyte imbalance during refeeding. Class-level.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

In animal models, insulin-induced hypoglycemia causes acute neuronal mitochondrial dysfunction; this is a consequence of the hypoglycemic adverse event that any insulin, including lispro, can cause at excess dose, not a separate toxic action of the drug used as intended.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: The same insulin-receptor pathway, at physiologic (non-hypoglycemic) exposure, is associated with increased mitochondrial protein synthesis and oxidative-phosphorylation activity in human muscle (see ATP production entry below; overlap disclosed in the overlap map), directly opposing a blanket "insulin harms mitochondria" reading.
  • At-risk subgroups: Recurrent or severe hypoglycemia, tight glycemic targets without adequate monitoring, hypoglycemia unawareness.

Regulatory status

Not addressed directly in the label; hypoglycemia itself is the label's primary warned adverse effect.

Population evidence

Animal/cell studies of insulin-induced hypoglycemia (Tier B, insulin type not confirmed as lispro specifically, treated as class-level): a 2019 study on sodium dichloroacetate addressing mitochondrial dysfunction and neuronal death following hypoglycemia-induced injury (PMID 31052436), and a 2020 study on nicotinamide mononucleotide administration after severe hypoglycemia improving neuronal survival and cognitive function in rats (PMID 32380185).

Mechanism

Named: during insulin-induced hypoglycemia, substrate (glucose) deprivation to neurons triggers mitochondrial permeability changes, calcium overload, and impaired oxidative metabolism, worsening during and immediately after the hypoglycemic episode.

Counter-evidence held on record

Physiologic (non-hypoglycemic) insulin exposure is mitochondrially supportive in a human muscle study (see ATP production), directly contradicting a general "insulin harms mitochondria" claim. This entry reflects burden created by the drug's known, dose-related adverse effect (hypoglycemia), not a direct toxic mechanism of insulin lispro used as intended. Per the outcome-versus-nutrient distinction (Hard Rule 2), this should never be read as evidence that correctly dosed insulin lispro damages mitochondria.

  • Effects of sodium dichloroacetate on mitochondrial dysfunction and neuronal death following hypoglycemia-induced injury (2019). PMID 31052436. — Animal/cell study on insulin-induced-hypoglycemia mitochondrial dysfunction; reactive-oxygen-species production during hypoglycemic injury.Insulin type used to induce hypoglycemia not confirmed as lispro specifically; treated as class-level.
  • Nicotinamide mononucleotide administration after severe hypoglycemia improves neuronal survival and cognitive function in rats (2020). PMID 32380185. — Animal study, insulin-induced severe hypoglycemia model, neuronal survival and cognitive outcomes.Insulin type not confirmed as lispro specifically; treated as class-level.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

Oxidative-stress evidence for insulin is direction-dependent: a class-level human study (other rapid- and long-acting insulin analogs, not lispro) reported altered oxidative-stress parameters during intensive insulin therapy in type 1 diabetes, while animal data link severe insulin-induced hypoglycemia specifically to reactive-oxygen-species generation and neuronal oxidative injury.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: Full quantitative direction and magnitude of the Radenković et al. 2023 finding (whether oxidative stress was higher or lower with intensive analog therapy versus controls) could not be confirmed from the abstract snippet accessed during this review; recorded as a limitation rather than asserted either way.
  • At-risk subgroups: Recurrent or severe hypoglycemia (for the hypoglycemia-linked component); intensively treated type 1 diabetes generally (for the class-level component, not lispro-specific).

Regulatory status

Not addressed in the label.

Population evidence

Radenković S et al., "The Effect of Therapy with Insulin Analogues (Aspart and Glargine) on Oxidative Stress Parameters in Patients with Type 1 Diabetes Mellitus," Acta Endocrinologica (Bucharest), 2023, PMID 38933255 (Tier C: insulin aspart and glargine studied, insulin lispro not in the cohort — class extrapolation). Separately, a 2008 animal/cell study found ketone bodies protected against oxidative damage induced during hypoglycemic conditions, implying reactive-oxygen-species generation during hypoglycemia itself (PMID 18339375, Tier B, insulin-induced hypoglycemia model, class-level).

Mechanism

Named for the hypoglycemia-linked finding: substrate deprivation during hypoglycemia promotes reactive-oxygen-species production in neurons, which ketone bodies were shown to mitigate. The mechanism behind the class-level intensive-therapy finding was not confirmed in the source snippet reviewed.

Counter-evidence held on record

The two evidence strands point in different directions/contexts (routine intensive therapy versus acute hypoglycemic episodes), which is itself recorded rather than resolved in either direction. Conflicting/direction-dependent evidence, and the human data is class-level (aspart, glargine), not insulin lispro-specific. Do not present as an established adverse effect of therapeutic insulin lispro dosing.

  • Radenković S et al. The Effect of Therapy with Insulin Analogues (Aspart and Glargine) on Oxidative Stress Parameters in Patients with Type 1 Diabetes Mellitus. Acta Endocrinologica (Bucharest). 2023. PMID 38933255. — Human study of intensive insulin-analogue therapy and oxidative-stress parameters in type 1 diabetes.Cohort: insulin aspart and glargine; insulin lispro was not in the studied cohort. Treated as class-level (Tier C) evidence, not lispro-specific. Full abstract/results could not be opened on a follow-up attempt (PubMed bot-verification block); direction/magnitude of the finding is not asserted beyond what the search-listing snippet showed.
  • Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions (2008). PMID 18339375. — Animal/cell study, ketone bodies preventing neuronal ATP decline and oxidative damage during hypoglycemia.Insulin type not confirmed as lispro specifically; treated as class-level.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No drug-specific or class-level evidence was confirmed that insulin, or insulin lispro specifically, alters copper status.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Searched PubMed with multiple phrasings ("insulin therapy copper zinc diabetes," "insulin treatment copper zinc diabetic rat"). Located animal studies describing diabetes disease-state trace-mineral disturbance (Failla & Kiser, "Hepatic and renal metabolism of copper and zinc in the diabetic rat," Am J Physiol, 1983, PMID 6824071 confirmed to exist via search listing) but could not open the full abstract, after repeated attempts, to confirm whether the study included an insulin-treatment arm and, if so, its direction of effect. Because this could not be confirmed by actually opening the source, it is not used to support a grade (per the prohibition on citing a source not opened). A human disease-state study ("Zinc, copper and magnesium status in insulin-dependent diabetes," 1994) examines diabetes itself, confounded by indication, not insulin therapy as the variable. No circulating consumer claim linking insulin to copper depletion was identified (though the consumer-claims sweep for this drug was not completed; see access notes). Both conditions for ungraded are met on the evidence actually verified.

Tooling note

PubMed individual-article pages (pubmed.ncbi.nlm.nih.gov/6824071/) repeatedly returned a bot-verification page instead of abstract content during this review; a targeted re-check of that specific citation is warranted in a future revision before this category can be graded with confidence either way.

  • Failla ML, Kiser RA. Hepatic and renal metabolism of copper and zinc in the diabetic rat. Am J Physiol. 1983. PMID 6824071. — Animal study (streptozotocin-diabetic rats), copper/zinc status in liver, kidney, intestine. Existence and basic citation confirmed via PubMed search listing.Full abstract could not be opened despite repeated attempts (PubMed bot-verification block); whether the study included an insulin-treatment arm, and its direction of effect, could not be confirmed. Not used to support any grade in this dossier for that reason.

Iron

Not graded — disclosed evidence gap

See study details

No drug-specific or class-level evidence was found that insulin lispro, or exogenous insulin therapy generally, alters iron status.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Searched PubMed for "insulin therapy iron ferritin status." Results concerned iron deficiency in dietary/vegetarian populations, hereditary hemochromatosis management, cardiometabolic risk associations, and iron-chelation effects on glucose metabolism in thalassemia — none testing exogenous insulin therapy's effect on iron metabolism as the studied variable. No circulating consumer claim linking insulin to iron depletion was identified. Both conditions for ungraded are met.

Tooling note

This search returned genuine, on-topic null results (not a blocked page), so the ungraded status reflects an actual literature gap for this specific drug-nutrient pairing rather than a tooling failure.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No drug-specific or class-level evidence was found that insulin, or insulin lispro specifically, alters gut microbiome composition or diversity.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Searched PubMed for "insulin therapy gut microbiome diabetes." The only result naming insulin therapy directly used gut microbiome composition as a predictor of who would go on to require insulin in gestational diabetes (reverse direction: microbiome predicting insulin need, not insulin altering microbiome). Other results concerned gut microbiota's role in diabetes disease states generally, or other interventions (exercise, metformin), not exogenous insulin as the studied variable. No circulating consumer claim linking insulin to microbiome disruption was identified. Both conditions for ungraded are met.

Tooling note

A planned follow-up query against the Europe PMC REST API to widen this search was blocked by proxy rate-limiting (repeated HTTP 429) and not completed; a future revision should re-check that channel specifically for this category.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production

Yellow — Low

See study details

A human insulin-infusion study found that physiologic insulin exposure increases skeletal-muscle mitochondrial ATP production and related gene transcription, while animal models show that insulin-induced hypoglycemia impairs neuronal ATP production; both are class-level (insulin type not confirmed as lispro), graded fully independent from the Mitochondrial burden and Oxygen delivery/utilization entries.

Full detail, limits and 3 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: The two mechanisms operate in opposite directions depending on glycemic context (physiologic insulin action versus a hypoglycemic overdose event), which is recorded explicitly rather than averaged into a single claim.
  • At-risk subgroups: None in the depletion sense for the supportive finding; recurrent/severe hypoglycemia for the impairing finding.

Regulatory status

Not addressed in the label.

Population evidence

Stump CS, Short KR, Bigelow ML, Schimke JC, Nair KS. "Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts." Proc Natl Acad Sci USA. 2003;100(13):7996-8001. PMID 12808136 (Tier C: human insulin-infusion study, insulin formulation not confirmed as lispro, class-level). Separately, hypoglycemia-injury animal studies (PMID 31052436, PMID 18339375; Tier B) implicate impaired ATP-generating capacity during severe hypoglycemic episodes.

Mechanism

Named for the supportive direction: insulin signaling enhances mitochondrial mRNA transcription and protein synthesis rates, increasing ATP production capacity. Named for the impairing direction: substrate deprivation during hypoglycemia suppresses oxidative ATP generation in neurons.

Counter-evidence held on record

The supportive (Stump et al.) and impairing (hypoglycemia-injury) findings directly counter each other in direction; both are retained because they describe different physiologic states (euglycemic insulin action versus hypoglycemic crisis), not a single contradicted claim. Not a basis for any supplement recommendation. Not to be merged with the Mitochondrial burden or Oxygen delivery/utilization entries (Hard Rule 7); overlap in underlying hypoglycemia-injury literature with Mitochondrial burden is disclosed in the overlap map.

  • Effects of sodium dichloroacetate on mitochondrial dysfunction and neuronal death following hypoglycemia-induced injury (2019). PMID 31052436. — Animal/cell study on insulin-induced-hypoglycemia mitochondrial dysfunction; reactive-oxygen-species production during hypoglycemic injury.Insulin type used to induce hypoglycemia not confirmed as lispro specifically; treated as class-level.
  • Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions (2008). PMID 18339375. — Animal/cell study, ketone bodies preventing neuronal ATP decline and oxidative damage during hypoglycemia.Insulin type not confirmed as lispro specifically; treated as class-level.
  • Stump CS, Short KR, Bigelow ML, Schimke JC, Nair KS. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA. 2003;100(13):7996-8001. PMID 12808136. — Human insulin-infusion study; increased mitochondrial ATP production, protein synthesis, and oxidative-phosphorylation gene transcription in skeletal muscle. PMID and journal/year confirmed via PubMed search listing.Insulin formulation used in the infusion protocol not confirmed as insulin lispro; treated as class-level (Tier C) evidence. Full abstract/results text (exact magnitude, diabetic-vs-control comparison) could not be opened during this review.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No drug-specific or class-level evidence was found that insulin lispro affects hemoglobin, hematocrit, red-cell mass, or tissue oxygen delivery.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Searched PubMed for insulin combined with erythropoietin, hemoglobin, and oxygen delivery/erythropoiesis (a first combined-term query returned zero results; a follow-up narrower query on "insulin erythropoietin" succeeded). All located results described erythropoietin's effect on insulin sensitivity and glucose metabolism (the reverse direction: EPO acting on insulin signaling, not insulin acting on erythropoiesis or oxygen delivery). No circulating consumer claim linking insulin to impaired oxygen delivery was identified. Both conditions for ungraded are met.

Tooling note

None beyond the general rate-limiting disclosed throughout; this category's null result reflects genuine, on-topic search returns across two separate query phrasings.

All references used above
  1. DailyMed, HUMALOG (insulin lispro) injection, solution — full prescribing information. — U.S. FDA-approved regulatory label. National Library of Medicine. Mechanism of action, pharmacokinetics, renal/hepatic impairment, drug interactions, hypokalemia warning.
  2. StatPearls: Insulin Lispro. — NCBI Bookshelf, NBK507840. Mechanism, pharmacokinetics (hepatic/renal degradation split), hypokalemia language specific to insulin lispro, monitoring, contraindications, drug interactions.
  3. StatPearls: Refeeding Syndrome. — NCBI Bookshelf, NBK564513. Mechanism of insulin-driven phosphate/potassium intracellular shift; states magnesium mechanism "less understood"; carbohydrate-metabolism thiamine demand. Class-level, not insulin lispro-specific.
  4. StatPearls: Insulin. — NCBI Bookshelf, NBK560688. General mechanism of action; electrolyte considerations noting hypokalemia risk especially with other hypokalemia-causing conditions/drugs. Class-level.
  5. Drugs.com professional monograph, Insulin Lispro. — Reproduces FDA label content; used to cross-confirm the potassium-shift and IV-monitoring language. Not counted as an independent Tier A source from the label.
  6. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, code A10AB04. — Confirms ATC classification (Insulins and analogues for injection, fast-acting) and defined daily dose (40 units) for insulin lispro.
  7. Lispro insulin and electrolyte supplementation for treatment of diabetic ketoacidosis in cats (2019). — Veterinary trial, n=12 cats (6 per group), lispro insulin protocol compared with regular insulin; reported low serum sodium, potassium, phosphate, and magnesium during treatment.Full journal name and PMID could not be confirmed during this review: the PubMed individual-article page returned a bot-verification challenge on repeated attempts. Details drawn from a PubMed search-results listing view only; a future revision should confirm full bibliographic detail before this source is relied on further.
  8. Radenković S et al. The Effect of Therapy with Insulin Analogues (Aspart and Glargine) on Oxidative Stress Parameters in Patients with Type 1 Diabetes Mellitus. Acta Endocrinologica (Bucharest). 2023. PMID 38933255. — Human study of intensive insulin-analogue therapy and oxidative-stress parameters in type 1 diabetes.Cohort: insulin aspart and glargine; insulin lispro was not in the studied cohort. Treated as class-level (Tier C) evidence, not lispro-specific. Full abstract/results could not be opened on a follow-up attempt (PubMed bot-verification block); direction/magnitude of the finding is not asserted beyond what the search-listing snippet showed.
  9. Effects of sodium dichloroacetate on mitochondrial dysfunction and neuronal death following hypoglycemia-induced injury (2019). PMID 31052436. — Animal/cell study on insulin-induced-hypoglycemia mitochondrial dysfunction; reactive-oxygen-species production during hypoglycemic injury.Insulin type used to induce hypoglycemia not confirmed as lispro specifically; treated as class-level.
  10. Nicotinamide mononucleotide administration after severe hypoglycemia improves neuronal survival and cognitive function in rats (2020). PMID 32380185. — Animal study, insulin-induced severe hypoglycemia model, neuronal survival and cognitive outcomes.Insulin type not confirmed as lispro specifically; treated as class-level.
  11. Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions (2008). PMID 18339375. — Animal/cell study, ketone bodies preventing neuronal ATP decline and oxidative damage during hypoglycemia.Insulin type not confirmed as lispro specifically; treated as class-level.
  12. Stump CS, Short KR, Bigelow ML, Schimke JC, Nair KS. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA. 2003;100(13):7996-8001. PMID 12808136. — Human insulin-infusion study; increased mitochondrial ATP production, protein synthesis, and oxidative-phosphorylation gene transcription in skeletal muscle. PMID and journal/year confirmed via PubMed search listing.Insulin formulation used in the infusion protocol not confirmed as insulin lispro; treated as class-level (Tier C) evidence. Full abstract/results text (exact magnitude, diabetic-vs-control comparison) could not be opened during this review.
  13. Failla ML, Kiser RA. Hepatic and renal metabolism of copper and zinc in the diabetic rat. Am J Physiol. 1983. PMID 6824071. — Animal study (streptozotocin-diabetic rats), copper/zinc status in liver, kidney, intestine. Existence and basic citation confirmed via PubMed search listing.Full abstract could not be opened despite repeated attempts (PubMed bot-verification block); whether the study included an insulin-treatment arm, and its direction of effect, could not be confirmed. Not used to support any grade in this dossier for that reason.
  14. Zinc, copper and magnesium status in insulin-dependent diabetes. 1994. PMID 7664536. — Human disease-state study; reduced serum zinc reported in insulin-dependent diabetes patients versus controls.Studies the diabetes disease state, not insulin therapy as the variable; confounded by indication (Hard Rule 6). Used only as background context for the Magnesium entry, not as supporting evidence for a drug effect.
  15. Walmsley RS. Refeeding syndrome: screening, incidence, and treatment during parenteral nutrition. J Gastroenterol Hepatol. 2013. PMID 24251716. — Narrative review; insulin release central to refeeding-syndrome pathophysiology and anabolic electrolyte/vitamin shifts. Class-level.
  16. De Silva A, Nightingale JMD. Refeeding syndrome: physiological background and practical management. Frontline Gastroenterol. 2020. PMID 32884632. — Narrative review; carbohydrate load raising plasma insulin and driving glucose/electrolyte shifts. Class-level.
  17. Maiorana A, Vergine G, Coletti V, et al. Acute thiamine deficiency and refeeding syndrome: similar findings but different pathogenesis. 2014. PMID 24985016. — Case-based discussion of thiamine deficiency in relation to electrolyte imbalance during refeeding. Class-level.